J
Jens Ulrich
Researcher at Otto-von-Guericke University Magdeburg
Publications - 88
Citations - 2782
Jens Ulrich is an academic researcher from Otto-von-Guericke University Magdeburg. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 22, co-authored 79 publications receiving 2249 citations.
Papers
More filters
Journal ArticleDOI
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
Ulrike Leiter,Rudolf Stadler,Cornelia Mauch,Werner Hohenberger,Norbert H. Brockmeyer,Carola Berking,Cord Sunderkötter,Martin Kaatz,Klaus-Werner Schulte,Percy Lehmann,Thomas Vogt,Jens Ulrich,Rudolf A. Herbst,Wolfgang Gehring,Jan-Christoph Simon,Ulrike Keim,Peter Martus,Claus Garbe +17 more
TL;DR: Results showed no difference in survival in patients treated with complete lymph node dissection compared with observation only, and complete lymph nodes dissection should not be recommended in patients with melanoma with lymph node micrometastases of at least a diameter of 1 mm or smaller.
Journal ArticleDOI
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Caroline J. Voskens,Simone M. Goldinger,Carmen Loquai,Caroline Robert,Katharina C. Kaehler,Carola Berking,Tanja Bergmann,Clemens L. Bockmeyer,Thomas Eigentler,Michael Fluck,Claus Garbe,Ralf Gutzmer,Stephan Grabbe,Axel Hauschild,Rüdiger Hein,Gheorghe Hundorfean,Armin Justich,Ullrich Keller,Christina Klein,Christine Mateus,Peter Mohr,Sylvie Paetzold,Imke Satzger,Dirk Schadendorf,Marc Schlaeppi,Gerold Schuler,Beatrice Schuler-Thurner,Uwe Trefzer,Jens Ulrich,Julia Vaubel,Roger von Moos,Patrik Weder,Tabea Wilhelm,Daniela Göppner,Reinhard Dummer,Lucie Heinzerling,Lucie Heinzerling +36 more
TL;DR: In this article, a wide spectrum of Ipilimumab-induced adverse events including drug rash with eosinophilia and systemic symptoms (DRESS), granulomatous inflammation of the central nervous system, and aseptic meningitis were documented.
Journal ArticleDOI
Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
TL;DR: Imiquimod as a single agent or in combination with intralesional IL-2 may be a promising immunomodulatory compound for the adjuvant topical treatment of patients with multiple cutaneous metastases of malignant melanoma.
Journal ArticleDOI
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma.
F Mornex,Luc Thomas,Peter Mohr,Axel Hauschild,Michèle Delaunay,Thierry Lesimple,Wolfgang Tilgen,B N Bui,Bernard Guillot,Jens Ulrich,S Bourdin,M Mousseau,Didier Cupissol,M E Bonneterre,C de Gislain,R J Bensadoun,M Clavel +16 more
TL;DR: Fotemustine plus whole brain irradiation delayed the time to cerebral progression of melanoma cerebral metastases compared with fotmustine alone but without a significant improvement in terms of objective control or overall survival.
Journal ArticleDOI
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node
Ulrike Leiter,Rudolf Stadler,Cornelia Mauch,Werner Hohenberger,Norbert H. Brockmeyer,Carola Berking,Cord Sunderkötter,Martin Kaatz,Kerstin Schatton,Percy Lehmann,Thomas Vogt,Jens Ulrich,Rudolf A. Herbst,Wolfgang Gehring,Jan-Christoph Simon,Ulrike Keim,D. Verver,Peter Martus,Claus Garbe +18 more
TL;DR: The final results of the German Dermatologic Cooperative Oncology Group trial with a median follow up of 72 months showed higher event rates, but similar HRs compared with those at the 3-year analysis, confirming that immediate CLND in SLN-positive patients is not superior to observation in terms of DMFS, RFS, or OS.